Guido Carloni, Monica Rinaldi^*

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2025.071847 - 24 February 2026

Abstract Hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are increasingly recognized as significant etiological factors in the pathogenesis of B-cell non-Hodgkin’s lymphomas (B-NHLs). Epidemiological and molecular studies have demonstrated a consistent association between chronic viral infection and B-NHLs. Multiple pathogenic mechanisms have been implicated in lymphomagenesis, both direct and indirect, including chronic antigenic stimulation, direct infection of B cells, and viral protein–mediated oncogenic signaling, It is likely that a combination of several pathogenic conditions is required to eventually lead to the development of lymphoma. The prevalence of B-cell lymphomas among individuals with chronic… More >

Yanfeng Wang^1,2,#, Xinyi Chen^1,2,#, Yichen Yin^1,2, Tao Li^3,*, Jing Chen^1,2,*

Oncology Research, Vol.34, No.3, 2026, DOI:10.32604/or.2026.068695 - 24 February 2026

Abstract Objectives: B-cell lymphoma 6 (BCL6) is a transcriptional repressor whose overexpression is closely linked to the progression of diffuse large B-cell lymphoma (DLBCL), making it a promising therapeutic target. This study aims to identify a novel small molecule, synthesized via proteolysis-targeting chimeras (PROTACs), capable of degrading BCL6, thereby inhibiting DLBCL growth and providing a foundation for future preclinical studies. Methods: The expression of BCL6 in DLBCL was analyzed using The Cancer Genome Atlas (TCGA) database and the Human Protein Atlas. Western blotting assays confirmed BCL6 expression in tumor cell lines, leading to the identification of… More >

Kayce Blumenstock^1,2, Vandana Zaman^2,3, Camille Green³, Narendra L. Banik^1,2,3, Azizul Haque^1,2,3,*

BIOCELL, Vol.49, No.10, pp. 1859-1871, 2025, DOI:10.32604/biocell.2025.068773 - 22 October 2025

Abstract Fc Receptor-Like 1 (FCRL1), a member of the FCRL family, contains two immunoreceptor tyrosine-based activation motifs (ITAMs) in its cytoplasmic domain and plays a critical role in B-cell biology. Its expression begins in pre-B-cells, dynamically shifts during B-cell development, and contributes to the regulation of human B-cell activation. Notably, FCRL1 is overexpressed in subsets of naive and memory B-cells, as well as in malignant B-cells, including those in diffuse large B-cell lymphoma (DLBCL), an aggressive and often treatment-resistant hematological malignancy. Among FCRL family members, FCRL1 stands out as a promising immunotherapeutic target due to its More >

Weiwei Chen¹, Xiaodie Zhou², Huiyu Li¹, Yuchen Yang¹, Lu Lu¹, Chunyan Zhu¹, Rong Fang¹, Xiaoyuan Chu¹, Shuping Zhou^3,*, Qian Sun^1,*

Oncology Research, Vol.33, No.8, pp. 2123-2139, 2025, DOI:10.32604/or.2025.063484 - 18 July 2025

Abstract Background: Primary bone marrow diffuse large B-cell lymphoma (PBM-DLBCL) represents an uncommon yet clinically aggressive hematologic malignancy. Despite its significant clinical impact, this entity lacks standardized diagnostic criteria in current WHO classifications. Methods: We performed a retrospective analysis of 55 PBM-DLBCL cases from our institutional database and published literature (2001–2022) to characterize disease features and identify prognostic factors, with particular focus on assessing how different treatment regimens influence therapeutic efficacy and long-term outcomes. Results: The data suggested a potential link between international prognostic index (IPI) scores and poorer survival, albeit without conclusive statistical evidence (p = More >

WEN YANG, BIN TANG, DAN XU, WENXIU YANG^*

Oncology Research, Vol.33, No.1, pp. 199-212, 2025, DOI:10.32604/or.2024.050036 - 20 December 2024

Abstract Background: The prognostic significance of the chemokine receptor CCR7 in diffuse large B-cell lymphoma (DLBCL) has been reported previously. However, the detailed mechanisms of CCR7 in DLBCL, particularly regarding its interaction with lenalidomide treatment, are not fully understood. Methods: Our study utilized bioinformatics approaches to identify hub genes in SU-DHL-2 cell lines treated with lenalidomide compared to control groups. Immunohistochemical data and clinical information from 122 patients with DLBCL were analyzed to assess the correlation of CCR7 and p-ERK1/2 expression with the prognosis of DLBCL. Furthermore, in vitro and in vivo experiments were conducted to clarify the… More > Graphic Abstract

D. Loganathan^1,*, M. Balasubramani¹, R. Sabitha², S. Karthik²

Computer Systems Science and Engineering, Vol.44, No.1, pp. 99-112, 2023, DOI:10.32604/csse.2023.023120 - 01 June 2022

Abstract Sensors are considered as important elements of electronic devices. In many applications and service, Wireless Sensor Networks (WSNs) are involved in significant data sharing that are delivered to the sink node in energy efficient manner using multi-hop communications. But, the major challenge in WSN is the nodes are having limited battery resources, it is important to monitor the consumption rate of energy is very much needed. However, reducing energy consumption can increase the network lifetime in effective manner. For that, clustering methods are widely used for optimizing the rate of energy consumption among the sensor… More >

Indra Mamad Gandidi^1,2,*, Edy Suryadi³, Efri Mardawati³, Dwi Rustam Kendarto³, Nugroho Agung Pambudi^4,*

Energy Engineering, Vol.119, No.3, pp. 1169-1178, 2022, DOI:10.32604/ee.2022.018821 - 31 March 2022

Abstract Pyrolysis is one of the thermal cracking methods to convert hydrocarbon to liquid fuel. The quantity and quality of the process are dependent on several condition including temperature, reaction time, catalyst, and the type of reactor. Meanwhile, a gasoline fraction was maximum product to be considered in the pyrolisis process. Therefore, this study aims to increase the gasoline fraction in liquid fuel using stepwise pyrolysis with a long bed catalytic reactor downstream (LBCR). The LBCR downstream was equipped with the top and bottom outlet and the fed source was mixed municipal solid waste (MMSW). The… More >

JIYU WANG^#, YING PAN^#, YANG WAN, ZHIXIANG WANYAN, ZHITAO WANG, QIANSHAN TAO, ZHIMIN ZHAI^*

BIOCELL, Vol.45, No.4, pp. 933-942, 2021, DOI:10.32604/biocell.2021.014280 - 22 April 2021

Abstract The present study aimed to clarify the role of SENEX in malignant cell proliferation in diffuse large B-cell lymphoma (DLBCL). 22 DLBCL patients (6 newly diagnosed cases, 7 cases at complete remission, and 9 relapsed cases) were included in the study. Our results indicated that both SENEX gene and protein were significantly increased in peripheral blood mononuclear cells (PBMCs) and tumor cells of relapsed DLBCL patients, accompanied by overexpression of p21, p16, and phosphorylated retinoblastoma (Rb). Silencing the SENEX gene in a DLBCL cell line caused a significant decrease in cell proliferation and inhibited cell cycle progression More >

Rabie A. Ramadan^1,2,*, Bassam W. Aboshosha³, Kusum Yadav¹, Ibrahim M. Alseadoon¹, Munawar J. Kashout¹, Mohamed Elhoseny^4,5

CMC-Computers, Materials & Continua, Vol.67, No.3, pp. 3563-3579, 2021, DOI:10.32604/cmc.2021.015519 - 01 March 2021

Abstract With the new era of the Internet of Things (IoT) technology, many devices with limited resources are utilized. Those devices are susceptible to a significant number of new malware and other risks emerging rapidly. One of the most appropriate methods for securing those IoT applications is cryptographic algorithms, as cryptography masks information by eliminating the risk of collecting any meaningful information patterns. This ensures that all data communications are private, accurate, authenticated, authorized, or non-repudiated. Since conventional cryptographic algorithms have been developed specifically for devices with limited resources; however, it turns out that such algorithms… More >

Qiuyun Luo^*†1, Wentao Pan^*†‡1, Suna Zhou^*†1, Guangfeng Wang^‡, Hanjie Yi^*§, Lin Zhang^*¶, Xianglei Yan^*†, Luping Yuan^*†, Zhenyi Liu^#, Jing Wang^**, Haibo Chen^#, MiaoZhen Qiu^*††, DaJun Yang^*†‡, Jian Sun^*‡‡

Oncology Research, Vol.28, No.4, pp. 331-344, 2020, DOI:10.3727/096504020X15825405463920

Abstract Despite therapeutic advances, the effective treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains a major clinical challenge. Evasion of apoptosis through upregulating antiapoptotic B-cell lymphoma-2 (BCL-2) family members and p53 inactivation, and abnormal activation of B-cell receptor signaling pathway are two important pathogenic factors for DLBCL. In this study, our aim is to explore a rational combination of BCL-2 inhibitor plus Bruton’s tyrosine kinase (BTK) blockade or p53 activation for treating DLBCL with the above characteristics. We demonstrated that a novel BCL-2 selective inhibitor APG-2575 effectively suppressed DLBCL with BCL-2 high expression… More >